How does sny make money?

sny generates $50.0B in annual revenue (annual revenue).

What is SNY's XVARY composite score?

sny (SNY) has an XVARY composite score of 80/100, rated above average. This combines growth, value, risk, and momentum factors.

SNY — sny stock analysis · xvary snapshot

Start here if you're new

what it is

Sanofi sells prescription drugs and vaccines around the world, then pours a large chunk of sales back into finding the next ones.

how it gets paid

Last year Sny made $50.0B in revenue. U.S. was the main engine at $30.4B, or 49% of sales.

what just happened

Last earnings came in at $1.36 EPS versus $1.20 expected, a 13.33% beat.

At a glance

A++ balance sheet — fortress balance sheet — as safe as it gets

45/100 earnings predictability — expect surprises

9.5% return on capital — nothing to write home about

xvary composite: 80/100 — above average

$62B fy2028 rev est

What they do

Sanofi sells prescription drugs and vaccines around the world, then pours a large chunk of sales back into finding the next ones.

Drugmaking is scale plus patience. Sanofi spent 18% of 2024 sales on R&D, which means you are backing a company that can fund long development cycles without blowing up its balance sheet. The balance sheet grade is A++, and that matters because failed trials are survivable when your finances are built like a bunker.

healthcare large-cap biopharma pipeline defensive

How they make money

$50.0B annual revenue

U.S.

$30.4B

+6.0%

Europe

$13.6B

+6.0%

Rest of world

$18.0B

+6.0%

R&D reinvestment base

$11.2B

flat

The products that matter

immunology blockbuster drug

Dupixent

$13B+ annual revenue · ~30% of sales

it drives roughly 30% of total sales today and loses patent protection in 2030. That is the core source of both Sanofi's strength and its biggest future problem.

center of gravity

newer launch portfolio

Altuviiio & Ayvakit

needed offset to a -5% vaccines decline

the snapshot does not give launch revenue, which tells you the real issue: these products matter less for size today than for whether they can help fill a $10B+ post-2030 gap.

pipeline bridge

preventive immunizations

Vaccines portfolio

$12.5B segment · -5%

this is still a $12.5B business, but it is moving the wrong way. When a quarter of your visible segment revenue is shrinking, the new launches have to do more than just look promising.

stabilizer, for now

Key numbers

18%

R&D intensity

That is the share of 2024 sales Sanofi reinvested into future drugs. Plain English: it is paying a large tax today for a chance at tomorrow's growth.

32.0%

operating margin

Operating margin means profit after running the business, before interest and taxes, so what: Sanofi keeps $0.32 from every $1 of sales at the operating line.

9.5%

return on capital

Return on capital means profit earned on the money tied up in the business, so what: decent, but not the kind of number that excuses a broken pipeline.

0.75

beta

Beta measures how jumpy a stock is versus the market, so what: Sanofi has been less volatile than the average stock.

Financial health

A++

strength

balance sheet grade A++ — the absolute highest — fortress balance sheet
risk rank 1 — safer than 95% of stocks
price stability 90 / 100
long-term debt $15.4B (12% of capital)
net profit margin 15.1% — keeps 15 cents of every dollar in revenue
return on equity 10% — $0.10 profit for every $1 investors have put in

A++ with balance sheet grade and risk rank standing out. your money faces less risk here than at most public companies.

Total return vs. market

You invested $10,000 in SNY 3 years ago → it's now worth $11,080.

The index would have given you $13,920.

same period. same starting point. SNY trailed the market by $2,840.

source: institutional data · total return

What just happened

beat estimates

Last earnings came in at $1.36 EPS versus $1.20 expected, a 13.33% beat.

Revenue still declined 0.92% vs. prior year, which is the contrast that matters. Profit beat the script, but sales did not exactly sprint. Recent company commentary said new launches like Altuviiio and Ayvakit helped offset pressure elsewhere.

$1.36

eps

0.92%

revenue vs. last year

77.5%

gross margin

the number that mattered

The 13.33% EPS beat matters because this stock is being sold as steady, and steady names get punished fast when they stop clearing low bars.

sanofi should deliver strong top- and bottom-line gains for the year soon ending.
third-quarter results rose at a solid pace, vs. prior year, both in euros and dollars.
sales were driven by new drug launches, namely altuviiio (hemophilia a) and ayvakit (mastocytosis, a rare disorder involving the skin and white blood cells), and ongoing strength of dupixent (for various immunological conditions), offset by a decline in the vaccines category, mostly due to competition and lower immunization rates.

meanwhile, disciplined spending, r&d prioritization, and operating efficiency, as well as repurchases under a buyback program of about $5.8 billion, helped lift earnings per adr. we expect increases in the fourth quarter, too, pushing up full-year 2025 sales and adr profits by double-digit clips, to $50.0 billion and $3.10, above our prior calls.
dupixent should remain a key contributor for a while.
we see this out to at least 2030, after which it is due to lose patent protection.

source: company earnings report, 2026

What could go wrong

the #1 risk is the Dupixent patent cliff in 2030. when one product drives roughly 30% of sales, the expiration date is not background noise — it's the story.

∘

med

Dupixent patent expiry

Dupixent generates $13B+ a year and roughly 30% of sales. If biosimilar pressure shows up after 2030 before new launches are large enough, Sanofi is staring at a $10B+ revenue gap.

impact: this is the valuation anchor and the reason 9.2x earnings looks cheap

∘

med

leadership reset

The snapshot flags a CEO change after a stalled turnaround. A strong balance sheet helps, but a strategy handoff in the middle of a pipeline transition is not a small operational detail.

impact: execution risk rises exactly when portfolio replacement matters most

∘

med

Vaccines erosion

Vaccines fell 5% in the snapshot period due to competition and lower immunization rates. That is a problem because the legacy businesses are supposed to fund the future, not create a second hole.

impact: a $12.5B segment shrinking makes the post-Dupixent bridge harder

∘

med

thin visible launch data

Altuviiio and Ayvakit are clearly important, but this snapshot does not show revenue scale for those launches. When the replacement assets are discussed more by name than by dollars, you should assume the proof is still forming.

impact: the bull case leans on products that still need to earn the right to matter

Sanofi has balance sheet time, not unlimited strategic time. The company still needs to prove it can replace a $10B+ revenue hole with more than one winning drug.

source: institutional data · regulatory filings · risk analysis

Pay attention to

earnings

Q1 2026 earnings report

Estimated for Apr 23, 2026. You want to see whether Dupixent strength still outweighs the drag from Vaccines.

leadership

first full strategy update from new management

A CEO change only matters if it changes capital allocation, pipeline priorities, or the pace of portfolio replacement.

concentration

Dupixent's share of sales

At roughly 30% of sales today, this number needs to peak before 2030 for the story to get safer from here.

segment health

whether Vaccines can stop shrinking

A -5% decline is manageable once. If it becomes the baseline, newer launches have to run faster just to keep Sanofi in place.

Analyst rankings

earnings predictability

45 / 100

This is below-average visibility for a company of this size. In human-speak, analysts do not see a clean, boring earnings story here.

risk rank

1

Risk rank 1 means the balance sheet and share-price behavior look safer than most stocks. Safe company. Less certain growth path.

source: institutional data

Institutional activity

institutions have been net selling for 2 consecutive quarters — 316 buyers vs. 333 sellers in 3q2025. total institutional holdings: 0.2B shares. net selling for 2 quarters.

source: institutional data · 1q2025-3q2025

source: institutional data

Price targets

3-5 year target range

$41 $74

$48 current price

$58 target midpoint · +21% from current · 3-5yr high: $70 (+45% · 14% ann'l return)

source: institutional data · analyst targets

The deep dive

SNY

xvary deep dive

sny

the full analysis is in the works.

what you'll get

dcf valuation model

bull / base / bear scenarios

competitive moat breakdown

quarterly earnings tracker

operating model projections

risk matrix with kill criteria

original price target + conviction

updated with every earnings

free · no spam · you'll be first to read it

sny

Get this snapshot in your inbox

Want the deeper analysis?